Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

← catalyst calendar

NCT06472245 · readout in 483 d

Sponsored by OSE Immunotherapeutics (industry) · OSE.PA — their whole pipeline →. With Exystat, GeneDx.

Phase

Phase 3

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

363estimated

Sites

207

Countries

Belgium, Canada, France +11

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-12-03

actual

When the study began enrolling

Primary completion

2027-12-15

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2028-12-15

estimated

The whole study's end, after follow-up

First posted

2024-06-25

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-23

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Patients With Non-Small Cell Lung Cancer

Interventions

Drug: OSE2101
Drug: Docetaxel
Device: NGS HLAA2 assay

Primary outcome

what the primary-completion date above is the date OF

OS defined as time from randomization to death

measured From randomization date through study completion, an average of 3 years

Publications

PMID 37704166 — reports results

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · OSE.PA's whole pipeline · Catalyst calendar · Every registered study · What changed